Incyte CEO highlights underappreciated pipeline and growth potential beyond Jakafi.

Incyte's new CEO, William Meury, shared insights at the Bank of America Healthcare Conference about his first year leading the company. He expressed optimism about Incyte's core business and pipeline, which he believes are undervalued by the market. Meury emphasized the company's potential for significant product development in the coming years, aiming to replace and surpass the success of their current drug, Jakafi, with multiple new growth drivers.